Project Grant F32AI181619
Award Date
9/25/24
Completion Date
6/30/27
Dollars Obligated
$252K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Rochester, NY 14611, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $228,825 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to New York University School of Medicine to conduct research on developing an effective HIV vaccine. The research aims to synergize neutralizing and non-neutralizing antibody responses targeting the HIV viral spike apex, based on insights from the success of COVID-19 vaccines. Specifically, the project will 1) design and validate a vaccine...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $737,761 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Pittsburgh to enhance HIV prevention through a vaccine approach that promotes durable immunity. The key objectives are to induce robust CD4 T follicular helper (Tfh) cells to facilitate the differentiation of germinal center B cells into plasma cells, thereby enhancing the persistence and avidity of HIV...
This federal Project Grant award of $107,948 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research aimed at engineering B cells to secrete broadly neutralizing antibodies that could help control HIV in people living with the virus. The key objectives are to: 1) design synthetic protein signaling molecules to enhance B cell function, 2) test the ability of these...
The federal Project Grant award, totaling $745,752 and awarded on July 19, 2024 by the National Institute of Allergy and Infectious Diseases (NIAID), supports research to develop a novel HIV-1 vaccine that can provide mucosal barrier protection. The grant is part of the NIAID's Allergy and Infectious Diseases Research program (CFDA 93.855), which funds research to advance the understanding, prevention, diagnosis, and treatment of infectious diseases and related conditions. The key focus of...
This $220,224 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports computational research on the assembly, maturation, and uncoating processes of the HIV-1 virus. The University of Chicago, the grant recipient, will investigate factors beyond the viral capsid that influence critical morphological transitions in the HIV-1 life cycle, such as the role of host cell factors and...
The federal Project Grant award of $500,000 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to identify and modulate molecular pathways that govern T cell antigen sensitivity in persons with HIV. The primary objectives are to: 1) Elucidate regulatory mechanisms governing antigen-refractory HIV-specific CD8+ T cells, 2) Define the contributions of HIV-infected antigen-refractory CD4+ T cells to...
This federal Project Grant award of $997,318, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to evaluate whether vaccine fractionation can improve the immunogenicity and protective efficacy of HIV vaccines using adenovirus type 26 (AD26) and mRNA-based platforms. The two specific aims of the research project are: 1) to assess whether vaccine fractionation, such as priming with a low dose...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to enhance the understanding of ADP-ribosylation (ADPR) and its role in HIV-1 latency and reactivation. The $285,816 award, spanning from September 2024 to October 2027, will fund research to identify global proteomic changes to ADPR during HIV-1 latency and reactivation, investigate PARP-HIV-1 interactions in...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the role of monocyte-derived galectin-1 in promoting tissue-resident memory T cell responses against influenza infections. The $722,958 award, made on November 22, 2024, will fund the University of Rochester's research to: Examine monocyte differentiation and the formation of memory T cells after...
This is a Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $108,256 grant is being provided to The Trustees of the University of Pennsylvania to conduct research aimed at harnessing broadly neutralizing antibodies (bNAbs) that target the V3-glycan patch on the HIV envelope protein in order to develop an effective HIV vaccine. The research involves a two-pronged approach: 1)...